Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: IPO investors get pre-IPO valuations
Analyst IPO Market Commentary
IPO investors are beginning to see pre-IPO valuations.
A biotech and a semiconductor company went public
this past week
after slashing their proposed valuations. While health care has remained strong all year, more
technology could be on the way
In the past 30 days, 85% of IPOs have priced below the original range, and 55% traded down or flat on the first day. Positive aftermarket trading has resulted in an average gain of 5% for the group, compared to an average loss of 5% for all 2015 IPOs. Pricing pressure appears to be paying off, but it may not be enough to reverse the trend.
could see as many as six IPOs, including two new biotechs and a telecom infrastructure company, along with a bank and two Chinese manufacturers that had previously made IPO attempts.
When the chips are down, Adesto gains 19%
Flash memory chip provider
) saw its valuation chipped down to $81 million from its originally proposed market cap of $170 million. Insiders also added a $3 million indication on the $25 million IPO. Adesto went public at $5 per share, below the average cost basis of insiders. It traded up 18% on its debut and finished the week up 19%. The company claims that its next-generation memory products extend the battery life of Internet of Things devices, but declining sales and gross margins likely led investor pushback.
Cut to the heart: MyoKardia drops valuation and trades up 2%
) cut its proposed valuation by 36% and raised $54 million at a market cap of $273 million. Instead of the proposed $16 price, it came public at $10, just above its April 2015 crossover round. The company gained 5% on the first day, but traded down a 2% gain by week-end. Formed by Third Rock Ventures and backed by Sanofi and Fidelity, MyoKardia in a Phase 1 trial for genetic defects in cardiac muscle contraction. Sanofi bought shares on the IPO, but the company had just one clinical candidate and the biotech sector has not fully recovered from its September sell-off. Another Third Rock/Sanofi/Fidelity biotech, Voyager (
), is scheduled for the week of November 9.
Pre-IPO fundraising has exploded in the past year, with private rounds for tech companies reportedly raising over ten times the capital of the public market. Biotechs, too, have increasingly IPO'd with large crossover funds behind them. However, capital raised in the private market could come under pressure if IPO investors refuse to pay an attractive premium to earlier rounds. Returns found in the current IPO market should weigh heavily on these funds' decisions.
Interactive Data acquired: Will LBOs IPO in the 4Q?
) was on file for an IPO that could have raised $700 million, but on Monday the LBO'd financial data provider announced that it would be acquired by Intercontinental Exchange for $5.2 billion. It had reportedly been planning to move forward with its IPO until First Data's (
) lackluster debut. Highly-leveraged Caribbean wireless provider Digicel (
) and grocery chain Albertsons (
) both postponed earlier this month, casting doubts over the timing of other high-profile LBOs in the IPO pipeline such as Neiman Marcus (
), Univision (
), McGraw-Hill Education (
) and Petco (
2 IPOs during the week of October 26, 2015
Deal size ($mm)
IPO price vs. midpoint
Return at 10/30
Adesto Technologies (
Flash memory chips
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO Market Snapshot
154 IPOs have raised $28.1 billion in 2015, but only 38% are trading above their IPO price. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index is down 5% year-to-date, compared to +1% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Twitter (
) and Hilton Worldwide (
). The Renaissance International IPO Index is down 3% year-to-date, in line with the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Recruit Holdings and Samsung C+T.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.